ライフサイエンスコーパス: pharmaceutical

1 s, proteins, amino acids, nucleic acids, and pharmaceuticals).

2 0311 based on mean rebate of 29% for branded pharmaceuticals).

3 ious fields ranging from electrochemistry to pharmaceuticals.

4 ination and screening potential NHR-targeted pharmaceuticals.

5 aging of proteins and the development of new pharmaceuticals.

6 of bioactive compounds as food additives or pharmaceuticals.

7 ty products with biological activity such as pharmaceuticals.

8 an inevitable step in the development of new pharmaceuticals.

9 unds which are the biological target of many pharmaceuticals.

10 lid-state forms and their complex changes in pharmaceuticals.

11 re prevalent in many commodity chemicals and pharmaceuticals.

12 he resin and reducing the resin capacity for pharmaceuticals.

13 ively screening surface water samples for 95 pharmaceuticals.

14 o the determination of dyes in beverages and pharmaceuticals.

15 broad substrate scope that includes complex pharmaceuticals.

16 itously found in ligands, agrochemicals, and pharmaceuticals.

17 of bioactive natural products and synthetic pharmaceuticals.

18 ns such as the preservation of protein-based pharmaceuticals.

19 iverse and promising feedstock for molecular pharmaceuticals.

20 ndocrine disruptor bisphenol A (BPA) and the pharmaceutical 17alpha-ethinyl estradiol (EE) are synthe

21 confidently detected the greatest number of pharmaceuticals (22) with only one false positive.

22 Cochrane Library, EMBASE, and International Pharmaceutical Abstracts from January 1994 to November 2

23 To facilitate future development of pharmaceuticals against antithrombin polymerization, an

24 erse range of reports from this field aim at pharmaceutical agent encapsulation, targeted drug-delive

25 e high-throughput toxicological screening of pharmaceutical agents and treatment regimens on organoty

26 Notably, structurally complex pharmaceutical agents could be functionalized or prepare

27 in ill-defined and there are no FDA approved pharmaceutical agents or medical countermeasures.

28 A range of novel pharmaceutical agents that aim to target liposarcoma-spe

29 verse effects of abused psychostimulants and pharmaceutical agents, and can be adapted for use in neu

30 ction in nanoscale drug delivery systems for pharmaceutical agents, including small molecules, protei

31 concentrations similar to those achieved by pharmaceutical agents, remarkably little is known about

32 heterocycles, as well as aromatic-containing pharmaceutical agents.

33 much attention because of its application to pharmaceuticals, agrochemicals, and late-stage functiona

34 nthetic strategy with useful applications in pharmaceuticals, agrochemicals, and materials chemistry.

35 cursors and transformation products of dyes, pharmaceuticals, agrochemicals, and other compound class

36 data in different application fields such as pharmaceutical analysis, agriculture, food chemistry, en

37 one of the most challenging tasks in modern pharmaceutical analysis.

38 y of building blocks for the construction of pharmaceutical and agrochemical agents.

39 id access to functionalized azines of direct pharmaceutical and agrochemical relevance.

40 o be used in personal health care, food, and pharmaceutical and cleaning industries.

41 cell biosensors have been seldom used in the pharmaceutical and cosmetics industries for preservative

42 ults provide a basis for novel approaches to pharmaceutical and diagnostic applications.

43 ith widespread applications in the chemical, pharmaceutical and energy sectors.

44 utilised fish into valuable products for the pharmaceutical and health food industries.

45 ntific fields such as chemical, biochemical, pharmaceutical and immunological purposes.

46 chemical engineering, materials science, or pharmaceutical and life science.

47 the FDA approved 222 novel therapeutics (183 pharmaceuticals and 39 biologics).

48 Consequently, a high proportion of pharmaceuticals and agrochemicals on the market today po

49 tly, to enlarge its use in foods, cosmetics, pharmaceuticals and agrochemicals preparations.

50 aily basis and these molecules also occur in pharmaceuticals and cosmetics.

51 The factors influencing bioaccumulation of pharmaceuticals and personal care products (PPCPs) in aq

52 The continuous release of pharmaceuticals and personal care products (PPCPs) into

53 lysis of complex mixtures of closely related pharmaceuticals and synthetic intermediates, including c

54 ients of 10 organic cations (including eight pharmaceuticals and two simple probe organic amines) wer

55 clinical analysis (markers, tumor cells, and pharmaceuticals) and in the detection of pathogenic micr

56 eactions, which are widely used in chemical, pharmaceutical, and polymer manufacturing.

57 ors of effluent quality including nutrients, pharmaceuticals, and estrogenicity improved in the efflu

58 d in a wide range of personal care products, pharmaceuticals, and food providing the opportunity for

59 olecules are ubiquitous in natural products, pharmaceuticals, and materials science.

60 s, including the synthesis of agrochemicals, pharmaceuticals, and materials.

61 -QTOF-MS/MS libraries containing pesticides, pharmaceuticals, and other environmental contaminants an

62 manufacture of various important chemicals, pharmaceuticals, and polymers.

63 ore hybrids endowed with unknown biological (pharmaceutical) annotations.

64 We also review the pharmaceutical application of pH-responsive polymeric ca

65 class of organisms developed exclusively for pharmaceutical application.

66 Decades of research support an interest in pharmaceutical applications for modulating BK channel fu

67 Despite numerous industrial and medicinal/pharmaceutical applications of its antioxidative feature

68 tes for various industrial, nutritional, and pharmaceutical applications.

69 functional ingredient in food, cosmetic and pharmaceutical applications.

70 no-engineered nano/biomaterials for food and pharmaceutical applications.

71 s that synthesize secondary metabolites with pharmaceutical applications.

72 at promise for agricultural, biomedical, and pharmaceutical applications.

73 to the development of improved clinical and pharmaceutical approaches.

74 Other isoxazole-based pharmaceuticals are probably also metabolized by a redox

75 nmental transformation and effects of chiral pharmaceuticals are stereoselective.

76 iological properties and wide application in pharmaceutical as well as agrochemical arenas.

77 ls, which suggests a cost-effective tool for pharmaceuticals as well as for educational purposes.

78 roach for the synthesis of agrochemicals and pharmaceuticals, as demonstrated by a four-step, telesco

79 Cell- or pharmaceutical-based therapeutics designed to prevent AA

80 applicable to other domains (food, cosmetic, pharmaceutical, biomedical).

81 entiator, ivacaftor (VX-770/Kalydeco, Vertex Pharmaceuticals, Boston, MA), as a therapeutic strategy

82 brane proteins are targets of most available pharmaceuticals, but they are difficult to produce recom

83 ections trends of, for example, hormones and pharmaceuticals by RO dense membranes.

84 t do not recognize stereochemistry of chiral pharmaceuticals by testing the hypothesis that environme

85 lachlor, atrazine, CIAT, glyphosate) and two pharmaceuticals (caffeine, metformin) with detection fre

86 tant structural motifs in organic chemistry, pharmaceutical chemistry, and materials science.

87 compounds, which are valuable motifs in the pharmaceutical chemistry, is highly atom- and step-econo

88 and widely used intermediates in organic and pharmaceutical chemistry.

89 ural biology, bioinformatics, analytical and pharmaceutical communities, and has formed the basis for

90 dle (MN) arrays has garnered interest in the pharmaceutical community.

91 analysis (MMPA), we combined data from three pharmaceutical companies and generated ADMET rules, avoi

92 environment, and insufficient investments by pharmaceutical companies are some of the clear reasons b

93 Pharmaceutical companies find drug development programs

94 e statements for accuracy, determine whether pharmaceutical companies from which the authors received

95 In contrast, since 2000, pharmaceutical companies have become increasingly profit

96 available P2RX7 knock-out mice generated by pharmaceutical companies possess certain splice variants

97 Many pharmaceutical companies recognise the advantages of rev

98 Every year pharmaceutical companies use significant resources to mi

99 on of methods for distinguishing biotech and pharmaceutical companies yields a dynamic, more accurate

100 data from completed studies sponsored by 13 pharmaceutical companies.

101 therapeutics under investigation in various pharmaceutical companies.

102 combinations through collaborations with 18 pharmaceutical companies.

103 Here I describe how partnering works in a pharmaceutical company and offer advice on how to make a

104 Deuterium- and tritium-labeled pharmaceutical compounds are pivotal diagnostic tools in

105 describe the retention times of a mixture of pharmaceutical compounds in hydrophilic interaction liqu

106 Indeed, sorption of two pharmaceutical compounds to 30 soils was better describe

107 processes such as cell cycle and response to pharmaceutical compounds.

108 active anthropogenic contaminants (biocides, pharmaceuticals) comprised 57% of 406 organics detected

109 ems should be designed based on the ultimate pharmaceutical concentration in ureolyzed urine.

110 Rising pharmaceutical costs in the United States are an increas

111 with a potential of becoming a bioenergy and pharmaceutical crop.

112 entation of policies at AMCs that restricted pharmaceutical detailing between 2006 and 2012 was assoc

113 disease pathways for treatment and targeted pharmaceutical development and above all highlight the r

114 ts into nuclear crowding, nucleic acid based pharmaceutical development, and nucleic acid based biose

115 diet-induced obesity and may be explored for pharmaceutical development.

116 illustrate and evaluate the approach for two pharmaceuticals (diclofenac and fluoxetine) and one pers

117 nophosphorus compounds in organic synthesis, pharmaceutical discovery agrochemical crop protection an

118 The potential use of this directing group in pharmaceutical drug discovery is illustrated by diversif

119 Aggregation of pharmaceutical drug products can occur during manufactur

120 ificant resources to mitigate aggregation of pharmaceutical drug products.

121 Representing important pharmaceutical drug targets, the corresponding G-protein

122 cient synthetic route for the preparation of pharmaceutical drugs, such as pitofenone and fenofibrate

123 of large neutral amino acids and a number of pharmaceutical drugs.

124 structures of bioactive natural products and pharmaceutical drugs.

125 lation normalized loads of illicit drugs and pharmaceuticals during a known period of high net fluctu

126 s (ABCs) have found numerous applications in pharmaceutical, electronics, environmental, cosmetics, a

127 ntains biologically active, pseudopersistent pharmaceuticals, even after treatment.

128 ter contains biologically active, long-lived pharmaceuticals, even after treatment.

129 activation in this manner may also allow for pharmaceutical exploration of other enzymes previously v

130 tive demand not only in traditional brewing, pharmaceutical, food and clinical industries but also in

131 are important to the agricultural, cosmetic, pharmaceutical, food and nutraceutical industry.

132 nic chemicals which find applications in the pharmaceutical, food processing, cosmetic and fine chemi

133 they were exposed to blue light (Blu-U, Dusa Pharmaceuticals) for 1000 seconds for a total fluence of

134 ated by the accurate determination of OME in pharmaceutical formulation and human serum samples with

135 etermination of ascorbic acid (vitamin C) in pharmaceutical formulation.

136 tegrates content for active ingredients with pharmaceutical formulations, indexing drugs and drug lab

137 for the detection of brucine in traditional pharmaceutical formulations.

138 r the sensing of COD in clinical samples and pharmaceutical formulations.

139 ontrol and routine determination of drugs in pharmaceutical formulations.

140 ompounds, which have various applications as pharmaceuticals, fragrances, and solvents.

141 The B1 content of pharmaceutical gentamicin is highly variable and major g

142 s study we show that the major components of pharmaceutical gentamicin lack PTC readthrough activity

143 arge enough to accommodate three-dimensional pharmaceutical guest molecules as opposed to planar, rig

144 The advent of antibody-drug conjugates as pharmaceuticals has fuelled a need for reliable methods

145 es, making remodeled BIH behave similarly to pharmaceutical heparin.

146 organic wastewater compounds (OWCs) such as pharmaceuticals, hormones, and detergents.

147 The widespread use of pharmaceuticals in both human and animal populations, an

148 mass spectrometric (MS/MS) analysis of nine pharmaceuticals in treated wastewater.

149 overy of valuable metabolites in biorefinery pharmaceutical industries and the disinfection of large-

150 ls, and therefore, it can be of interest for pharmaceutical industries as a high-throughput BBB penet

151 As both food and pharmaceutical industries show growing interest in tropi

152 crobial sanitation technologies for food and pharmaceutical industries.

153 A prices due to negotiation between BMoH and pharmaceutical industries.

154 find applications in the food, cosmetic and pharmaceutical industries.

155 Extracts could be used in the food and pharmaceutical industries.

156 c protein could be used in food, cosmetic or pharmaceutical industries.

157 able biomass in the food, feed, chemical and pharmaceutical industries.

158 plains the increasing engagement of both the pharmaceutical industry and academia towards the discove

159 ral facet of drug discovery campaigns in the pharmaceutical industry and academia.

160 accuracy.Traditional approaches used in the pharmaceutical industry are not precise or versatile eno

161 The pharmaceutical industry focuses the bulk of its efforts

162 e proteins as drug targets, and although the pharmaceutical industry has been focusing on these recep

163 of interest and scientific momentum, as the pharmaceutical industry has come to appreciate the role

164 Research in both academia and the pharmaceutical industry has led to the development of se

165 The pharmaceutical industry has responded to this challenge

166 By contrast, the rise of the modern pharmaceutical industry in the past century has been bas

167 entional Trials) guideline authors (n = 16), pharmaceutical industry statisticians (n = 3), journal e

168 lishment and sustained growth of the steroid pharmaceutical industry, the production of highly functi

169 tocol for cFAE and its widespread use in the pharmaceutical industry, the reaction mechanism has not

170 attrition rates of lead compounds within the pharmaceutical industry, which are often a result of scr

171 es is becoming increasingly important in the pharmaceutical industry.

172 ning protein 4, a prominent cancer target in pharmaceutical industry.

173 ct that could be of interest for food and/or pharmaceutical industry.

174 amines are valuable building blocks for the pharmaceutical industry.

175 heteroaromatic systems commonly used in the pharmaceutical industry.

176 y intermediates in organic synthesis and the pharmaceutical industry.

177 t but immensely worthwhile challenge for the pharmaceutical industry.

178 l carrier can lower the amount of the active pharmaceutical ingredient (API) required in cancer treat

179 h NADP(H) and also with both NADP(H) and the pharmaceutical ingredient (R)-rasagiline are reported.

180 dicated attention is given to a novel active pharmaceutical ingredient-ionic liquid (API-IL) concept,

181 sure and monitor the concentration of active pharmaceutical ingredients (API) in powder blends in the

182 for achieving high concentrations of active pharmaceutical ingredients (API) per nano-liposome that

183 ystems have improved the syntheses of active pharmaceutical ingredients (APIs), natural products, and

184 ve delivery technology for a range of active pharmaceutical ingredients (APIs).

185 macologic actions and indications for active pharmaceutical ingredients approved by FDA and other reg

186 pproach towards the identification of active pharmaceutical ingredients by comparing drug interaction

187 inetics, and have synthesised several active pharmaceutical ingredients in automated reconfigurable s

188 ncement in delivery of a broad set of active pharmaceutical ingredients including small molecules, pr

189 ns for the application of identifying active pharmaceutical ingredients, an essential step to assess

190 osit nanostructured films of small molecular pharmaceutical ingredients, including caffeine, paraceta

191 ample, in the industrial synthesis of active pharmaceutical ingredients.

192 show that T cell-specific deletion and early pharmaceutical inhibition of acetyl CoA carboxylase 1, t

193 Here, we investigated the outcome of pharmaceutical inhibition of PHD in mice with MALA induc

194 /+) and p53(-/-) HCT116 cells in response to pharmaceutical inhibition of the proteasome (by MG-132)

195 the PRC2 (Polycomb Repressive Complex 2) by pharmaceutical inhibition or siRNA reduced the levels of

196 ate pathway enzyme gene expression, and used pharmaceutical inhibitors, atorvastatin, alendronate or

197 are one of the most versatile and promising pharmaceutical innovations for countering heterogeneous

198 ality is strong, such that both academic and pharmaceutical institutions are now entering this intere

199 to various aryl thioether building blocks of pharmaceutical interest.

200 oss is a major public health concern with no pharmaceutical intervention for hearing protection or re

201 ic islets and may represent a new target for pharmaceutical intervention to potentially prevent T1D.

202 otential use of genetic information to guide pharmaceutical intervention to prevent adverse pregnancy

203 These type 2 cytokines are targets for pharmaceutical intervention, and a number of therapeutic

204 nts with CHS and could be a novel target for pharmaceutical intervention.

205 onal modulation of Mvarphis by pathogens and pharmaceutical interventions at the signal transduction

206 different genes opens the way for developing pharmaceutical interventions designed to relieve ER stre

207 during and after primary treatment, whereas pharmaceutical interventions did not (WES, 0.09; 95% CI,

208 and the relevance of such for development of pharmaceutical interventions.

209 ietary components, industrial chemicals, and pharmaceuticals into metabolites with altered activities

210 l chemicals, consumer product chemicals, and pharmaceuticals is well documented in waters in the U.S.

211 r and eight antiandrogens that contained the pharmaceuticals ketoconazole and theophylline and severa

212 one furoate, and triamcinolone acetonide are pharmaceutical mainstays to treat chronic inflammatory d

213 be of sufficient concern, it may require the pharmaceutical manufacturer of the drug in question to c

214 ry 2010 to March 2016, reference mining, and pharmaceutical manufacturers.

215 stion is of interest for scientists, food or pharmaceutical manufacturers.

216 lled redox state and rate is crucial for its pharmaceutical/medicinal applications.

217 Due to hydrolysis of pharmaceutical metabolites back to the parent compound,

218 ets was affected by exposure to caffeine and pharmaceutical mixture treatments.

219 of alkenes has streamlined the production of pharmaceuticals, natural products, fine chemicals and ot

220 nt desensitized states as a new strategy for pharmaceutical neuroprotection.

221 re spending on inpatient, ambulatory, retail pharmaceutical, nursing facility, emergency department,

222 This study assessed the effects of common pharmaceuticals on a cosmopolitan saprophagous insect, M

223 This study assessed the effects of common pharmaceuticals on an agricultural pest, Trichoplusia ni

224 Owing to the failure of the present pharmaceutical options, such as carboplatin a metallodru

225 are significantly better than the available pharmaceutical options.

226 been and are increasingly used in food/feed, pharmaceutical or cosmetic industries.

227 verning the approval of chemicals for use as pharmaceuticals or release into the environment.

228 ademic research and clinical, environmental, pharmaceutical, or biotechnological analysis being poten

229 d compositional information from biomedical, pharmaceutical, or clinical samples, among others.

230 trategies as it is for pharmacotherapies and pharmaceutical-oriented prevention strategies.

231 f use in signaling the controlled release of pharmaceutical payloads.

232 lant defence compounds with potential use as pharmaceuticals, pesticides and other high-value product

233 Importantly, C-N bond-containing pharmaceuticals, Piribedil and Cinnarizine, have been sy

234 plications, spanning from the preparation of pharmaceutical polymeric carriers, to the formulation of

235 ted in surface waters; however, whether this pharmaceutical poses a risk to aquatic organisms is deba

236 olatile flavor, used in foods, cosmetics and pharmaceuticals, possessing also insect repellent activi

237 ogenesis in AD pathogenesis, and implicate a pharmaceutical potential for targeting the APP673 site f

238 ogenesis in AD pathogenesis, and implicate a pharmaceutical potential for targeting the APP673 site f

239 osynthesis of triptolide, a diterpenoid with pharmaceutical potential.

240 mple opportunity to improve the precision of pharmaceutical practice.

241 c treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and es

242 mixture of chemical contaminants, including pharmaceuticals, present in discharges of wastewater tre

243 ring, but also on other applications such as pharmaceutical processing and energy storage.

244 duced recombinant human factor H a promising pharmaceutical product for therapeutic intervention in p

245 idently confirming the active component in a pharmaceutical product.

246 time feedback for reaction monitoring during pharmaceutical production to favor the more bioavailable

247 we explore the application of omega-TAms for pharmaceutical production.

248 It has been included in various pharmaceutical products because of several beneficial pr

249 omprises production stocks, agricultural and pharmaceutical products, chemical waste dumps, and analy

250 es are one of the fastest growing classes of pharmaceutical products, however, their potential is lim

251 aterial in dietary supplements, cosmetic and pharmaceutical products, or as a source of bioactive com

252 First, the market entry prices of innovator pharmaceutical products, or brand drugs and biologics, a

253 time release testing (RTRt) for manufactured pharmaceutical products.

254 heir widespread use in foods, cosmetics, and pharmaceutical products.

255 Optimization of a protein's pharmaceutical properties is usually carried out by rati

256 eta1-selective neutral antagonists with good pharmaceutical properties that can potentially overcome

257 processing steps for medical diagnostics and pharmaceutical purification.

258 ase processes has spurred efforts to develop pharmaceutical regulators of their activity.

259 represent a large class of metabolites with pharmaceutical relevance.

260 metabolites in urine significantly impacted pharmaceutical removal, by competing for ion-exchange si

261 centers (AMCs) enacted policies restricting pharmaceutical representative sales visits to physicians

262 PARs have been the subject of major pharmaceutical research efforts but the discovery of sma

263 Pharmaceutical research requires pre-clinical testing of

264 erivatives that are of potential interest to pharmaceutical research were synthesized within minutes

265 he fundamental basis for molecular design in pharmaceutical research, biocatalysis, and agrochemical

266 behind these complex phenomena is crucial in pharmaceutical research.

267 unpleasant smell, the risk of pathogens, and pharmaceutical residue.

268 linical utility of predictive algorithms for pharmaceutical response in AUD.

269 center implementation of policies regulating pharmaceutical salesperson visits to attending physician

270 of ultra-trace RIF amounts in biological and pharmaceutical samples with satisfactory recovery data.

271 re photoionization was examined for food and pharmaceutical samples.

272 evaluation of ifosfamide in real (biological/pharmaceutical) samples with detection limit as low as 0

273 groundwork for label-free drug screening in pharmaceutical science and industry.

274 edients for its use in the food, cosmetic or pharmaceutical sector.

275 I, $38.7-$49.6) billion of this increase was pharmaceutical spending.

276 Imiquimod (Aldara 5% cream; 3M Pharmaceuticals, St Paul, Minn) was applied twice a week

277 e 2009, the imiquimod- or Aldara-induced (3M Pharmaceuticals, St. Paul, MN) model of acute skin infla

278 as autism and schizophrenia, a new promising pharmaceutical strategy is to study the interaction betw

279 Over time, many pharmaceutical studies were conducted, changing clinical

280 cological screening, biomedical research and pharmaceutical studies, to date no satisfactory technolo

281 r Ras and Fyn, but potentially applicable to pharmaceutical targets involved in a variety of human di

282 ce of G protein-coupled receptors (GPCRs) as pharmaceutical targets, there has been an immense intere

283 Access to pharmaceuticals, technology, blood, and organs for trans

284 The QSRR-DoE computed retention time of pharmaceutical test analytes and subsequently calculated

285 velopment is likely to be more amenable to a pharmaceutical than a food delivery route, these organis

286 further development of pulmonary surfactant pharmaceuticals that better mimic the physiological self

287 drug metabolism predictions, and developing pharmaceuticals that have a decreased ability to undergo

288 t has been shown for selected tertiary amine pharmaceuticals that they react with ozone and form the

289 lants also contribute high concentrations of pharmaceuticals to the environment.

290 Efforts to identify pharmaceuticals to treat heritable metabolic liver disea

291 The efficacy of currently approved pharmaceutical treatments is limited mainly to acute inf

292 be taken into account for the development of pharmaceutical treatments of Alzheimer's disease.

293 because of the advantages that personalized pharmaceutical treatments would offer.

294 These findings suggest a role for pharmaceuticals tuning the neuroimmune system as therape

295 ulation normalization showed that per capita pharmaceutical use remained unchanged during the period

296 of contaminants of emerging concern, such as pharmaceuticals, using a risk-based approach to ecotoxic

297 chemists, and pharmacologists together with pharmaceutical venture capitalist companies.

298 Herein, 131 pharmaceuticals were tested for their effect on CYP27A1-

299 s) in synthetic urine can selectively remove pharmaceuticals with minimal coremoval of nutrients to e

300 thyl compounds have led to their ubiquity in pharmaceuticals, yet their chemical properties have made